Condition
Progressive Brain Metastases
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Terminated1
Recruiting1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02429570Not ApplicableActive Not Recruiting
Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
NCT02896335Phase 2Recruiting
Palbociclib and Pembrolizumab In Central Nervous System Metastases
NCT02166658Phase 2Terminated
A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
Showing all 3 trials